Effect of TECAR (Transfer of Energy Capacitive and Resistive) Therapy on Chronic Supraspinatus Tendinitis

NCT07316712 | Not Yet Recruiting

• 1 other identifier: P.T.REC/012/005900
• Study Type: interventional
• Target: 46
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to investigate the effect of TECAR therapy on pain, shoulder range of motion, functional disability, and handgrip strength in patients with grade II supraspinatus tendinitis.

Conditions

Supraspinatus Tendinitis

Outcome Measures

Primary Outcomes (1)

• Assessment of Pain Intensity of Shoulder Joint by Numerical Rating Scale (NRS)

  The Numerical Rating Scale (NRS) will evaluate shoulder pain when using the NRS. Patients will be asked to rate their pain on a scale from 0 to 10, where 0 represents "no pain" and 10 represents "the worst pain possible.

  3 weeks

Secondary Outcomes (4)

• Assessment of Shoulder abduction range of motion

  3 weeks

• Assessment of Shoulder External Rotation range of motion

  3 weeks

• Assessment of Handgrip strength by handheld dynamometer

  3 weeks

• Assessment of Functional disability by QuickDASH Scale (Arabic Version)

  3 weeks

Study Arms (2)

Conventional treatment + TECAR therapy

EXPERIMENTAL

The experimental group will receive conventional physiotherapy sessions as the active comparator group, in addition to TECAR therapy at the end of each session. Sessions will be received for three weeks (nine sessions, three times per week).

Other: Conventional treatment; Device: TECAR (Transfer of Energy Capacitive and Resistive) Therapy

Conventional treatment

ACTIVE COMPARATOR

The active comparator group will receive conventional physiotherapy sessions for three weeks (nine sessions, three times per week).

Other: Conventional treatment

Interventions

Conventional treatment OTHER

All patients in both groups will receive conventional treatment, 3 sessions per week for 3 weeks. The conventional methods for treating supraspinatus tendinitis include shoulder swings, painless range of motion (ROM) exercises, shoulder joint active-assisted exercises, resistance exercises to improve muscle strength, and pain-reducing physiotherapy modalities like ultrasound.

Conventional treatment; Conventional treatment + TECAR therapy

TECAR (Transfer of Energy Capacitive and Resistive) Therapy DEVICE

Patients in the experimental group only will receive TECAR therapy, 3 sessions per week for 3 weeks. The treatment will start with an automatic capacitive energy transfer for 10 minutes. Next, the capacitive plaque will be replaced by the resistive electrode, and the neutral electrode will be fixed

Conventional treatment + TECAR therapy

Eligibility Criteria

• Age: 30 Years - 55 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Supraspinatus Tendinitis grade II based on Neer's classification, confirmed by special tests, signs, and symptoms of grade I and II Supraspinatus Tendinitis for the past month, and taking non-steroidal anti-inflammatory drugs as suggested by the physician.
• All patients will have a body mass index between 18.5 and 29.9 kg/m².

You may not qualify if:

• Other grades of Supraspinatus Tendinitis.
• Any past shoulder surgical interventions.
• Instability of the shoulder joint due to other reasons, Acromioclavicular Joint Arthritis.
• Non-cooperative subjects.
• Diabetes
• Pregnant or lactating women.
• Serious neuromuscular or cardiovascular diseases.
• Systemic illness and severe COVID-19 cases will be excluded from this study.
• Pacemakers
• Heat Sensitivity
• Metal Implants

Sponsors & Collaborators

• Cairo University: lead

Study Sites (1)

CAN Center outpatient clinic

Cairo, Egypt

Location

MeSH Terms

Interventions

Therapeutics

Study Officials

• Hanaa Kenawy Atta, PhD

  Assistant Professor, Cairo University

  STUDY CHAIR

• Hend Hamdy Mohamed Ahmed, PhD

  Lecturer, Cairo university

  STUDY DIRECTOR

Central Study Contacts

Mohamed Gamal Ibrahem Alghamry, B.Sc

CONTACT

+20 114 448 1731; Mohamed.gamal.2651997@gmail.com

Hend Hamdy Mohamed Ahmed, PhD

CONTACT

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: December 19, 2025
• First Posted: January 5, 2026
• Study Start: December 30, 2025
• Primary Completion: February 15, 2026
• Study Completion: February 28, 2026
• Last Updated: January 5, 2026

Record last verified: 2025-12

Locations

EG (1)